Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goserelin - AstraZeneca

Drug Profile

Goserelin - AstraZeneca

Alternative Names: Goserelin acetate implant; ZD-9393; Zoladex

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; TerSera Therapeutics
  • Class Antineoplastics; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Prostate cancer; Uterine haemorrhage
  • Phase II Salivary gland cancer

Most Recent Events

  • 31 May 2019 Interim efficacy data from a phase III GETUG-AFU 16 trial in prostate cancer were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 05 Sep 2018 AstraZeneca plans the LARES phase III trial for Breast Cancer (Early stage disease) in China (NCT03658213)
  • 20 Nov 2017 AstraZeneca completes a phase III trial in Breast cancer (Late-stage disease, In adults, In the elderly) in Thailand, Taiwan, Philippines, South Korea, India and Japan (SC) (NCT01073865)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top